Faze Medicines launches with $81M Series A, Alnylam vet heading science in play at biomolecular condensates

Kyle Blankenship

Once mostly unknown to the larger scientific world, the field of biomolecular condensates — cellular structures that could have big implications on neurodegenerative research — has seen …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Faze Medicines launches with $81M Series A, Alnylam vet heading science in play at biomolecular condensates

Kyle Blankenship

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

Faze Med­i­cines launch­es with $81M Se­ries A, Al­ny­lam vet head­ing sci­ence in play at bio­mol­e­c­u­lar con­den­sates

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Faze Medicines launches with $81M Series A, Alnylam vet heading science in play at biomolecular condensates